Galectin-3, a lately discovered β-galactoside-binding protein expressed on tumor cells (93), was described as NKp30 inhibitor, restraining NKp30-mediated NK functions and tumor escape elimination by NK cells (93, 94). The gene discussed is NCR3; the disease is neoplasm.